Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Clinical Research
  • Published:

Common genetic and clinical risk factors: association with fatal prostate cancer in the Cohort of Swedish Men



Clinical variables—age, family history, genetics—are used for prostate cancer risk stratification. Recently, polygenic hazard scores (PHS46, PHS166) were validated as associated with age at prostate cancer diagnosis. While polygenic scores are associated with all prostate cancer (not specific for fatal cancers), PHS46 was also associated with age at prostate cancer death. We evaluated if adding PHS to clinical variables improves associations with prostate cancer death.


Genotype/phenotype data were obtained from a nested case–control Cohort of Swedish Men (n = 3279; 2163 with prostate cancer, 278 prostate cancer deaths). PHS and clinical variables (family history, alcohol intake, smoking, heart disease, hypertension, diabetes, body mass index) were tested via univariable Cox proportional hazards models for association with age at prostate cancer death. Multivariable Cox models with/without PHS were compared with log-likelihood tests.


Median age at last follow-up/prostate cancer death was 78.0 (IQR: 72.3–84.1) and 81.4 (75.4–86.3) years, respectively. On univariable analysis, PHS46 (HR 3.41 [95% CI 2.78–4.17]), family history (HR 1.72 [1.46–2.03]), alcohol (HR 1.74 [1.40–2.15]), diabetes (HR 0.53 [0.37–0.75]) were each associated with prostate cancer death. On multivariable analysis, PHS46 (HR 2.45 [1.99–2.97]), family history (HR 1.73 [1.48–2.03]), alcohol (HR 1.45 [1.19–1.76]), diabetes (HR 0.62 [0.42–0.90]) all remained associated with fatal disease. Including PHS46 or PHS166 improved multivariable models for fatal prostate cancer (p < 10–15).


PHS had the most robust association with fatal prostate cancer in a multivariable model with common risk factors, including family history. Adding PHS to clinical variables may improve prostate cancer risk stratification strategies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Data availability

Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) Consortium data are available upon request to the Data Access Committee ( Questions and requests for further information may be directed to

Code availability

Code used for this work is stored in an institutional repository and will be shared upon request to the corresponding author.


  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.

    Article  PubMed  Google Scholar 

  2. Seibert TM, Fan CC, Wang Y, Zuber V, Karunamuni R, Parsons JK, et al. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. BMJ. 2018;360:1–7.

    Article  Google Scholar 

  3. Shoag JE, Nyame YA, Gulati R, Etzioni R, Hu JC. Reconsidering the trade-offs of prostate cancer screening. N Engl J Med. 2020;382:2465–8.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Loeb S, Lilja H, Vickers A. Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer. Curr Opin Urol. 2016;26:459–65.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Ström P, Nordström T, Aly M, Egevad L, Grönberg H, Eklund M. The Stockholm-3 model for prostate cancer detection: algorithm update, biomarker contribution, and reflex test potential. Eur Urol. 2018;74:204–10.

    Article  PubMed  Google Scholar 

  6. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate. 1990;17:337–47.

    Article  CAS  PubMed  Google Scholar 

  7. Bratt O, Drevin L, Akre O, Garmo H, Stattin P. Family history and probability of prostate cancer, differentiated by risk category: a Nationwide Population-Based Study. J Natl Cancer Inst. 2016;108:djw110.

    Article  PubMed  Google Scholar 

  8. Rawla P. Epidemiology of prostate cancer. World J Oncol. 2019;10:63–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Baquet CR, Horm JW, Gibbs T, Greenwald P. Socioeconomic factors and cancer incidence among blacks and whites. J Natl Cancer Inst. 1991;83:551–7.

    Article  CAS  PubMed  Google Scholar 

  10. Albright F, Stephenson RA, Agarwal N, Teerlink CC, Lowrance WT, Farnham JM, et al. Prostate cancer risk prediction based on complete prostate cancer family history. Prostate. 2015;75:390–8.

    Article  PubMed  Google Scholar 

  11. Giri VN, Beebe-Dimmer JL. Familial prostate cancer. Semin Oncol. 2016;43:560–5.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Zhao J, Stockwell T, Roemer A, Chikritzhs T. Is alcohol consumption a risk factor for prostate cancer? A systematic review and meta-analysis. BMC Cancer. 2016;16:845.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007;121:1571–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Witte JS. Personalized prostate cancer screening: Improving PSA tests with genomic information. Sci Transl Med. 2010;2:62ps55.

    Article  CAS  PubMed  Google Scholar 

  15. Taylor RA, Fraser M, Rebello RJ, Boutros PC, Murphy DG, Bristow RG, et al. The influence of BRCA2 mutation on localized prostate cancer. Nat Rev Urol. 2019;16:281–90.

    Article  PubMed  Google Scholar 

  16. Huynh-Le M-P, Fan CC, Karunamuni R, Martinez ME, Eeles RA, Kote-Jarai Z, et al. Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nat Commun. 2021;12:1236.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Karunamuni R, Huynh-Le M-P, Fan C, Thompson W, Eeles R, Kote-Jarai Z, et al. African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. Int J Cancer. 2020.

  18. Discacciati A, Orsini N, Andersson S-O, Andren O, Johansson J-E, Mantzoros CS, et al. Coffee consumption and risk of localized, advanced and fatal prostate cancer: a population-based prospective study. Ann Oncol. 2013;24:1912–8.

    Article  CAS  PubMed  Google Scholar 

  19. Rylander-Rudqvist T, Håkansson N, Tybring G, Wolk A. Quality and quantity of saliva DNA obtained from the self-administrated oragene method—a pilot study on the cohort of Swedish men. Cancer Epidemiol Biomark Prev. 2006;15:1742–5.

    Article  CAS  Google Scholar 

  20. Karunamuni RA, Huynh-Le M-P, Fan CC, Eeles RA, Easton DF, Kote-Jarai ZS, et al. The effect of sample size on polygenic hazard models for prostate cancer. Eur J Hum Genet. 2020.

  21. Abdel-Rahman O. Prostate cancer incidence and mortality in relationship to family history of prostate cancer; findings from the PLCO Trial. Clin Genitourin Cancer. 2019.

  22. Therneau TM, Li H. Computing the Cox model for case cohort designs. Lifetime Data Anal. 1999;5:99–112.

    Article  CAS  PubMed  Google Scholar 

  23. Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, et al. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. Nat Genet. 2018;50:928–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Karunamuni RA, Huynh-Le M-P, Fan CC, Thompson W, Eeles RA, Kote-Jarai Z, et al. Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. Prostate Cancer Prostatic Dis. 2021:1–10.

  25. Wolf AMD, Wender RC, Etzioni RB, Thompson IM, D’Amico AV, Volk RJ, et al. American Cancer Society Guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin. 2010;60:70–98.

    Article  PubMed  Google Scholar 

  26. Goldgar DE, Easton DF, Cannon-albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst. 1994;86:1600–8.

    Article  CAS  PubMed  Google Scholar 

  27. Rodriguez C, Calle EE, Miracle-McMahill HL, Tatham LM, Wingo PA, Thun M, et al. Family history and risk of fatal prostate cancer. Epidemiology. 1997;8:653–7.

    Article  CAS  PubMed  Google Scholar 

  28. Hemminki K. Familial risk and familial survival in prostate cancer. World J Urol. 2012;30:143–8.

    Article  PubMed  Google Scholar 

  29. Barber L, Gerke T, Markt SC, Peisch SF, Wilson KM, Ahearn T, et al. Family history of breast or prostate cancer and prostate cancer risk. Clin Cancer Res. 2018;24:5910–7.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Adami HO, McLaughlin JK, Hsing AW, Wolk A, Ekbom A, Holmberg L, et al. Alcoholism and cancer risk: a population-based cohort study. Cancer Causes Control. 1992;3:419–25.

    Article  CAS  PubMed  Google Scholar 

  31. Brunner C, Davies NM, Martin RM, Eeles R, Easton D, Kote-Jarai Z, et al. Alcohol consumption and prostate cancer incidence and progression: a Mendelian Randomisation Study. Int J Cancer. 2017;140:75–85.

    Article  CAS  PubMed  Google Scholar 

  32. Ratna A, Mandrekar P. Alcohol and cancer: mechanisms and therapies. Biomolecules. 2017;7.

  33. Fall K, Garmo H, Gudbjörnsdottir S, Stattin P, Zethelius B. Diabetes mellitus and prostate cancer risk; a nationwide case-control study within PCBaSe Sweden. Cancer Epidemiol Biomark Prev. 2013;22:1102–9.

    Article  CAS  Google Scholar 

  34. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia. 2004;47:1071–8.

    Article  CAS  PubMed  Google Scholar 

  35. Beckmann K, Crawley D, Nordström T, Aly M, Olsson H, Lantz A, et al. Association between antidiabetic medications and prostate-specific antigen levels and biopsy results. JAMA Netw Open. 2019;2:e1914689.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Hankinson SJ, Fam M, Patel NN. A review for clinicians: prostate cancer and the antineoplastic properties of metformin. Urol Oncol Semin Orig Investig. 2017;35:21–29.

    Article  CAS  Google Scholar 

  37. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. Version 1.2019.

  38. NCCN Guidelines Version 1.2019 Older Adult Oncology. 2019.

  39. Huynh-Le M-P, Fan CC, Karunamuni R, Walsh EI, Turner EL, Lane JA, et al. A genetic risk score to personalize prostate cancer screening, applied to population data. Cancer Epidemiol Biomark Prev. 2020;29:1731–8.

    Article  Google Scholar 

  40. Huynh-Le MP, Myklebust TÅ, Feng CH, Karunamuni R, Johannesen TB, Dale AM, et al. Age dependence of modern clinical risk groups for localized prostate cancer—a population-based study. Cancer. 2020;126:1691–9.

    Article  PubMed  Google Scholar 

  41. DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI, et al. Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA Cancer J Clin. 2016;66:290–308.

    Article  PubMed  Google Scholar 

Download references


This study was funded in part by grants from the University of California (#C21CR2060), the United States National Institute of Health/National Institute of Biomedical Imaging and Bioengineering (#K08EB026503), the Research Council of Norway (#223273), KG Jebsen Stiftelsen, and South East Norway Health Authority. The content is solely the responsibility of the authors and does not necessarily represent the official views of any of the funding agencies, who had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Author information

Authors and Affiliations



Corresponding author

Correspondence to Tyler M. Seibert.

Ethics declarations

Conflict of interest

TMS reports honoraria from Multimodal Imaging Services Corporation for imaging segmentation and honoraria from Varian Medical Systems and WebMD, Inc. for educational content. AMD has additional disclosures outside the present work: founder, equity holder, and advisory board member for CorTechs Labs, Inc.; advisory board member of Human Longevity, Inc.; recipient of nonfinancial research support from General Electric Healthcare. CCF is a scientific consultant for CorTechs Labs, Inc.

Ethics approval

All contributing studies were approved by the relevant ethics committees and performed in accordance with the Declaration of Helsinki; written informed consent was obtained from the study participants. The present analyses used de-identified data from the PRACTICAL consortium and have been approved by the review board at the corresponding authors’ institution.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Huynh-Le, MP., Karunamuni, R., Fan, C.C. et al. Common genetic and clinical risk factors: association with fatal prostate cancer in the Cohort of Swedish Men. Prostate Cancer Prostatic Dis 24, 845–851 (2021).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links